Background Real‐world data in patients with moderate psoriasis treated with apremilast is
limited. Objectives To evaluate the effectiveness and safety of apremilast in bio‐naïve …

Background Apremilast is an oral phosphodiesterase‐4 inhibitor indicated for patients with
moderate‐to‐severe chronic plaque psoriasis and active psoriatic arthritis. Objectives To …

Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe
and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

Abstract Introduction While several European studies have reported real-world apremilast
use, patient-perceived benefits, and treatment satisfaction, local reimbursement criteria for …

Introduction Psoriasis is a chronic inflammatory condition that can significantly impact the
quality of life (QoL), regardless of the level of skin involvement. Apremilast is indicated for …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Introduction In the real-world APPRECIATE study (NCT02740218), most patients with
psoriasis demonstrated notable improvements on disease severity measures and reported …

Background Treating to absolute treatment targets rather than relative measures such as
Psoriasis Area and Severity Index (PASI)‐75 is emerging as an important clinical concept …